Supplementary Table S7. Patients with or without Gorlin syndrome with five common TEAEs associated with vismodegib treatment ongoing at the time of treatment discontinuation and at each safety follow-up assessment. TEAE Patients with Gorlin syndrome and AEs Ongoing, (%) n 52 n  At treatment Months after treatment discontinuation 1 month 3 months 6 months 9 months 12 months Muscle 32 (61.5) 22 (42.3) 9 (17.3) 6 (11.5) 3 (5.8) 2 (3.8) spasm Alopecia 35 (67.3) 30 (57.7) 19 (36.5) 9 (17.3) 6 (11.5) 5 (9.6) Ageusia 7 (13.5) 6 (11.5) 4 (7.7) 2 (3.8) 1 (1.9) 1 (1.9) Dysgeusia 29 (55.8) 20 (38.5) 9 (17.3) 5 (9.6) 4 (7.7) 4 (7.7) Weight 22 (42.3) 21 (40.4) 14 (26.9) 9 (17.3) 4 (7.7) 4 (7.7) decreased TEAE Patients without Gorlin syndrome and AEs Ongoing, (%) n 214 n  Months after treatment
Supplementary Table S7. Patients with or without Gorlin syndrome with five common TEAEs associated with vismodegib treatment ongoing at the time of treatment discontinuation and at each safety follow-up assessment. TEAE Patients with Gorlin syndrome and AEs Ongoing, n (%) n  52 At treatment discontinuation Months after treatment 1 month 3 months 6 months 9 months 12 months Muscle spasm 32 (61.5) 22 (42.3) 9 (17.3) 6 (11.5) 3 (5.8) 2 (3.8) Alopecia 35 (67.3) 30 (57.7) 19 (36.5) 9 (17.3) 6 (11.5) 5 (9.6) Ageusia 7 (13.5) 6 (11.5) 4 (7.7) 2 (3.8) 1 (1.9) 1 (1.9) Dysgeusia 29 (55.8) 20 (38.5) 9 (17.3) 5 (9.6) 4 (7.7) 4 (7.7) Weight decreased 22 (42.3) 21 (40.4) 14 (26.9) 9 (17.3) 4 (7.7) 4 (7.7) TEAE Patients without Gorlin syndrome and AEs Ongoing, n (%) n  214 Months after treatment